Troriluzole free base

Troriluzole, a third-generation, tripeptide proagent of Riluzole , is an orally active glutamate modulator.

For research use only. Not for human or veterinary use.

Target mGluR

Research area Neurological DiseaseCancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Troriluzole structure

CAS No.: 1926203-09-9

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 365.00	BP-02418-10mg	In stock	Get quote
25 mg	USD 730.00	BP-02418-25mg	In stock	Get quote
50 mg	USD 1,170.00	BP-02418-50mg	In stock	Get quote
100 mg	USD 1,870.00	BP-02418-100mg	In stock	Get quote
250 mg	USD 3,740.00	BP-02418-250mg	In stock	Get quote
500 mg	Inquire	BP-02418-500mg	In stock	Inquire
1 g	Inquire	BP-02418-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Related forms

BP-02418A — Troriluzole HCl

Description

Troriluzole, a third-generation, tripeptide proagent of Riluzole , is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .

Biological activity

In Vitro Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases.

Identifiers

SMILES: O=C(CN(C)C(CNC(CN)=O)=O)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
InChIKey: YBZSGIWIPOUSHY-UHFFFAOYSA-N

Specifications

MW (average): 419.3790
Formula: C₁₅H₁₆F₃N₅O₄S
CAS No.: 1926203-09-9
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 50 mg/mL

Documents

References

[1].Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012.

[2].Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18.